InSightec Invites RSNA 2014 Attendees to Learn About its MR-Guided Focused Ultrasound Solution for Treatment of Uterine Fibroids and Alleviation of Pain Caused by Bone Metastases

HAIFA, Israel, November 25, 2014 /PRNewswire/ --

InSightec, world leader in MR-guided Focused Ultrasound (MRgFUS) will be on site at the RSNA 100^th annual meeting to present its MR-guided Focused Ultrasound solution for ablation of uterine fibroids and alleviation of pain caused by bone metastases.

InSightec's non-invasive therapeutic technology is at the forefront of re-purposing the MRI suite from a purely diagnostic platform into a tool for delivering advanced care to patients in an ambulatory setting.

InSightec representatives will be on-site at the RSNA to discuss the recent announcement made by the Health Care Service Corporation (HCSC) to include coverage of InSightec's solution for pain palliation of bone metastases, opening the door to many patients who suffer from metastatic bone disease and have not responded to, or have rejected, radiation therapy.

InSightec has also finalized the enrolment of the FDA pivotal study for its neurosurgery application on Essential Tremor. Current clinical investigations for the technology also include treatments of prostate cancer, liver cancer, pancreas cancer, and breast cancer.

In addition to showcasing its solutions, InSightec will also proudly present its new corporate identity, designed to accentuate the company's values around innovation, precision, clinical effectiveness, positive outcomes and accessibility while giving the company a more contemporary, future-facing and updated look and feel.

We invite you to visit InSightec at the GE booth 3539, talk to our representatives, see a demonstration and learn more about our unique non-invasive technological solution that is transforming patient care around the world.

Note to editors 

ABOUT INSIGHTEC 

INSIGHTEC is the global leader for providing therapeutic Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) solutions. A pioneer in the field, the company was founded in 1999 with investment and support from GE Healthcare. Today, we provide non-invasive commercial solutions for the treatment of uterine fibroids and pain palliation of bone metastases when radiation therapy is not an option, with investigational studies underway for several other clinical applications. With a growing global install base, our treatment platform is the showpiece of some of the world's most renowned medical care facilities and has been featured in nearly 100 peer-reviewed articles.

A leader in medical research and development, InSightec has received numerous awards, including the Wall Street Journal Technology Award and The European Union's IST Grand Prize. Business Week called the InSightec platform "one of the 25 ideas for a changing world" while TIME Magazine included it among the 50 best innovations. The company is privately held by GE Healthcare, Elbit Imaging, York Capital Management, GEOC Hengtong Investment Limited Partnership and MediTech Advisors.

For more information please visit: http://www.insightec.com

Media Contact
Xen Mendelsohn Aderka
VP of Marketing
[email protected]
+972-4-8131309

SOURCE InSightec

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED